Versor Investments LP Acquires New Position in GoodRx Holdings, Inc. (NASDAQ:GDRX)

Versor Investments LP bought a new position in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm bought 11,700 shares of the company’s stock, valued at approximately $54,000.

A number of other large investors also recently bought and sold shares of GDRX. EP Wealth Advisors LLC acquired a new stake in shares of GoodRx during the 3rd quarter valued at approximately $73,000. Sanctuary Advisors LLC acquired a new stake in shares of GoodRx during the third quarter worth $85,000. Quest Partners LLC bought a new position in shares of GoodRx in the 3rd quarter worth about $160,000. JPMorgan Chase & Co. boosted its holdings in shares of GoodRx by 358.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 24,293 shares of the company’s stock valued at $169,000 after buying an additional 18,997 shares during the period. Finally, Sugar Maple Asset Management LLC bought a new stake in shares of GoodRx during the 4th quarter valued at about $122,000. Institutional investors own 63.77% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on GDRX. Morgan Stanley cut their target price on shares of GoodRx from $7.00 to $6.00 and set an “equal weight” rating on the stock in a report on Tuesday, December 17th. Mizuho initiated coverage on GoodRx in a report on Wednesday, December 4th. They issued a “neutral” rating and a $5.00 price target on the stock. KeyCorp lowered their price objective on GoodRx from $7.00 to $6.00 and set an “overweight” rating for the company in a research note on Wednesday, January 8th. Wells Fargo & Company dropped their target price on GoodRx from $9.00 to $8.00 and set an “overweight” rating on the stock in a research report on Friday, February 28th. Finally, Barclays lowered their price target on shares of GoodRx from $10.00 to $6.00 and set an “overweight” rating for the company in a research report on Monday, November 11th. Three investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $8.18.

GoodRx Trading Down 3.7 %

NASDAQ:GDRX opened at $4.67 on Wednesday. The stock has a market cap of $1.78 billion, a price-to-earnings ratio of -155.67, a PEG ratio of 2.46 and a beta of 1.28. The company has a debt-to-equity ratio of 0.70, a quick ratio of 5.48 and a current ratio of 5.48. GoodRx Holdings, Inc. has a 1 year low of $4.09 and a 1 year high of $9.26. The business has a fifty day moving average of $4.72 and a 200-day moving average of $5.70.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.